Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,746.00
Bid: 4,732.00
Ask: 4,736.00
Change: 70.00 (1.50%)
Spread: 4.00 (0.085%)
Open: 4,676.00
High: 4,857.00
Low: 4,666.00
Prev. Close: 4,676.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of global vaccine adjuvant specialist

17 Dec 2018 07:00

RNS Number : 6004K
Croda International PLC
17 December 2018
 

17 December 2018

 

Croda International Plc

 

Acquisition of global vaccine adjuvant specialist

 

Croda International Plc ('Croda') today announces that a definitive agreement has been signed with Brenntag Nordic A/S to acquire Brenntag Biosector A/S ('Biosector'). Biosector is a specialist in the manufacture and supply of adjuvants serving the human and veterinary vaccine market. The total consideration is €72 million in cash and the transaction is expected to close by the end of 2018.

 

Biosector was founded in 1939 and operates from a GMP-certified adjuvants manufacturing facility in Frederikssund, Denmark. Its product portfolio comprises innovative aluminium and saponin-based adjuvants. Aluminium-based adjuvants are extensively used in human and veterinary vaccines to increase their effectiveness. They also provide a platform to introduce new technically advanced saponin-based adjuvants.

 

Vaccine adjuvants are a natural extension to Croda's market leading, high-purity excipient delivery systems in its Health Care business. These adjuvants represent a niche, high-growth market, driven by increased healthcare spending alongside advances in biotechnology and the growing need for preventative treatments. Biosector is differentiated through its high quality portfolio of adjuvants, with a strong position in human applications.

 

On completion, Biosector will be integrated into Croda's Health Care business within the Life Sciences sector. It will continue to be led by its dedicated team, all of whom have extensive, class leading credentials and pharmaceutical experience. Croda will leverage its formulation and purification expertise to accelerate the development of Biosector's rich pipeline of next generation adjuvant systems. Croda will also utilise its dedicated global sales network to deliver Biosector's growth potential.

 

Steve Foots, Chief Executive of Croda, commented:

 

"Biosector is a rare asset, in a high value, fast growing sector of the global pharmaceutical market. With an experienced high-quality team, Biosector brings world-class protected technologies and industry-leading manufacturing facilities. Furthermore, the strong cultural alignment between Biosector and Croda enhances our highly technical-based sales approach and emphasis on value over volume. The opportunity to quickly build upon Biosector's impressive track record to date is enormously exciting and we look forward to welcoming the team to Croda."

 

Further information:

Investors: Conleth Campbell, VP Investor Relations, Croda Tel: +44 1405 860 551

Media: Charlie Armitstead, Teneo Tel: +44 20 3603 5220

 

About Croda:

 

Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world's biggest and most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.

 

Croda has a network of over 4,300 passionate and committed employees, working together as one global team across manufacturing sites and offices in 37 countries. Croda is a FTSE100 company with a flexible structure that allows it to focus on developing and delivering innovative, sustainable ingredients that its customers can build on in: Personal Care, Life Sciences (Health Care and Crop Care), Performance Technologies (Smart Materials, Energy Technologies, Home Care & Water Treatment) and Industrial Chemicals.

www.croda.com 

 

About Brenntag:

 

Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio. Headquartered in Essen, Germany, the company operates a global network with more than 530 locations in 73 countries and a workforce of more than 16,000 employees. In 2017, the company generated sales of EUR 11.7 billion (USD 13.3 billion). Brenntag connects chemical manufacturers and chemical users. The company supports its customers and suppliers with tailor-made distribution solutions for industrial and specialty chemicals. With over 10,000 products and a world-class supplier base, Brenntag offers one-stop-shop solutions to around 185,000 customers. This includes specific application technology, an extensive technical support and value-added services such as just-in-time delivery, product mixing, formulation, repackaging, inventory management and drum return handling. Long-standing experience and local excellence in the individual countries characterise the global market leader for chemical distribution.

www.brenntag.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQGGGBCPUPRGUQ
Date   Source Headline
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:00 amRNSDirector/PDMR Shareholding
6th Mar 20199:58 amRNSDirector/PDMR Shareholding
6th Mar 20199:57 amRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSResults for the year ended 31 December 2018
12th Feb 20194:47 pmRNSDirector/PDMR Shareholding
11th Jan 20194:21 pmRNSDirector/PDMR Shareholding
31st Dec 20187:00 amRNSAcquisition completion
17th Dec 20187:00 amRNSAcquisition of global vaccine adjuvant specialist
12th Dec 20181:14 pmRNSDirector/PDMR Shareholding
22nd Nov 20181:54 pmRNSDirector Declaration
22nd Nov 20188:07 amRNSDirector/PDMR Shareholding
14th Nov 20182:48 pmRNSDirector/PDMR Shareholding
14th Nov 20188:24 amRNSDirector/PDMR Shareholding
1st Nov 20187:00 amRNSTrading Update for the Third Quarter 2018
26th Oct 20187:00 amRNSAcquisition update
12th Oct 20181:42 pmRNSDirector/PDMR Shareholding
4th Oct 20183:03 pmRNSDirector/PDMR Shareholding
4th Oct 20183:01 pmRNSDirector/PDMR Shareholding
28th Sep 20183:35 pmRNSDirector/PDMR Shareholding
11th Sep 20184:50 pmRNSDirector/PDMR Shareholding
6th Sep 20184:07 pmRNSDirector/PDMR Shareholding
5th Sep 20187:00 amRNSAppointment of Broker
22nd Aug 201811:06 amRNSDirector Declaration
13th Aug 20184:37 pmRNSDirector/PDMR Shareholding
7th Aug 20189:11 amRNSDirector/PDMR Shareholding
31st Jul 20184:16 pmRNSDirector/PDMR Shareholding
25th Jul 20184:19 pmRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20182:27 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSDirector/PDMR Shareholding
12th Jun 20184:04 pmRNSDirector/PDMR Shareholding
11th Jun 20182:02 pmRNSDirector/PDMR Shareholding
31st May 20183:41 pmRNSDirector/PDMR Shareholding
25th May 20182:09 pmRNSDirector/PDMR Shareholding
11th May 20184:31 pmRNSDirector/PDMR Shareholding
26th Apr 20183:57 pmRNSDirector/PDMR Shareholding
26th Apr 20189:16 amRNSResult of AGM
25th Apr 20187:00 amRNSTrading Update for the First Quarter 2018
20th Apr 201811:14 amRNSDirectorate Change
20th Apr 20187:00 amRNSDirectorate Change
19th Apr 20189:47 amRNSDirector/PDMR Shareholding
19th Apr 20189:44 amRNSDirector/PDMR Shareholding
11th Apr 20181:09 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSCapital Markets Event
3rd Apr 20182:19 pmRNSDirector/PDMR Shareholding
28th Mar 20182:39 pmRNSDirector/PDMR Shareholding
28th Mar 20182:38 pmRNSDirector/PDMR Shareholding
28th Mar 201812:19 pmRNSScheme of Arrangement becomes Effective

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.